These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 26339367)

  • 1. HER2 status in molecular apocrine breast cancer: associations with clinical, pathological, and molecular features.
    Guo W; Wang W; Zhu Y; Zhu X; Shi Z; Wang Y
    Int J Clin Exp Pathol; 2015; 8(7):8008-17. PubMed ID: 26339367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
    He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
    World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of SATB1 and HER2 in breast cancer and the correlations with clinicopathologic characteristics.
    Liu X; Zheng Y; Qiao C; Qv F; Wang J; Ding B; Sun Y; Wang Y
    Diagn Pathol; 2015 May; 10():50. PubMed ID: 25956130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlations between HER2 Expression and Other Prognostic Factors in Breast Cancer: Inverse Relations with the Ki-67 Index and P53 Status.
    Payandeh M; Shahriari-Ahmadi A; Sadeghi M; Sadeghi E
    Asian Pac J Cancer Prev; 2016; 17(3):1015-8. PubMed ID: 27039719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Basal-like immunophenotype markers and prognosis in early breast cancer.
    Cassol L; Silveira Graudenz M; Zelmanowicz A; Cancela A; Werutsky G; Rovere RK; Garicochea B
    Tumori; 2010; 96(6):966-70. PubMed ID: 21388060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heat shock protein 27 and gross cystic disease fluid protein 15 play critical roles in molecular apocrine breast cancer.
    Liu X; Feng C; Liu J; Zhao L; Liu J; Zhang W; Liu N; Niu Y
    Tumour Biol; 2016 Jun; 37(6):8027-36. PubMed ID: 26711786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The updated 2018 American Society of Clinical Oncology/College of American Pathologists guideline on human epidermal growth factor receptor 2 interpretation in breast cancer: comparison with previous guidelines and clinical significance of the proposed in situ hybridization groups.
    Woo JW; Lee K; Chung YR; Jang MH; Ahn S; Park SY
    Hum Pathol; 2020 Apr; 98():10-21. PubMed ID: 32027910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concordance of breast cancer biomarker status between routine immunohistochemistry/in situ hybridization and Oncotype DX qRT-PCR with investigation of discordance, a study of 591 cases.
    Sechrist H; Glasgow A; Bomeisl P; Gilmore H; Harbhajanka A
    Hum Pathol; 2020 Oct; 104():54-65. PubMed ID: 32758491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The importance of EGFR as a biomarker in molecular apocrine breast cancer.
    Liu X; Feng C; Liu J; Liu J; Li C; Xu C; Niu Y
    Hum Pathol; 2018 Jul; 77():1-10. PubMed ID: 29409930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human epidermal growth factor receptor 2 expression in breast cancer: correlation with clinical pathological features.
    Ning SF; Li JL; Luo CP; Wei CH; Lu YK; Liu HZ; Wei WE; Zhang LT
    Int J Clin Exp Pathol; 2014; 7(12):8740-7. PubMed ID: 25674240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer.
    Bauer K; Parise C; Caggiano V
    BMC Cancer; 2010 May; 10():228. PubMed ID: 20492696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p63 expression is associated with high histological grade, aberrant p53 expression and TP53 mutation in HER2-positive breast carcinoma.
    Guo S; Wang Y; Rohr J; Shang L; Ma J
    J Clin Pathol; 2021 Oct; 74(10):641-645. PubMed ID: 32873702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
    Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G
    Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy.
    Krystel-Whittemore M; Xu J; Brogi E; Ventura K; Patil S; Ross DS; Dang C; Robson M; Norton L; Morrow M; Wen HY
    Breast Cancer Res Treat; 2019 Aug; 177(1):61-66. PubMed ID: 31144151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses' Health Study.
    Marotti JD; Collins LC; Hu R; Tamimi RM
    Mod Pathol; 2010 Feb; 23(2):197-204. PubMed ID: 19898422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular subtype can predict the response and outcome of Chinese locally advanced breast cancer patients treated with preoperative therapy.
    Chen XS; Wu JY; Huang O; Chen CM; Wu J; Lu JS; Shao ZM; Shen ZZ; Shen KW
    Oncol Rep; 2010 May; 23(5):1213-20. PubMed ID: 20372832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Confirmation of a low HER2 positivity rate of breast carcinomas - limitations of immunohistochemistry and in situ hybridization.
    Vogel UF
    Diagn Pathol; 2010 Jul; 5():50. PubMed ID: 20670419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression.
    Umemura S; Takekoshi S; Suzuki Y; Saitoh Y; Tokuda Y; Osamura RY
    Oncol Rep; 2005 Aug; 14(2):337-43. PubMed ID: 16012712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Basal Protein Expression Is Associated With Worse Outcome and Trastuzamab Resistance in HER2+ Invasive Breast Cancer.
    Chung A; Choi M; Han BC; Bose S; Zhang X; Medina-Kauwe L; Sims J; Murali R; Taguiam M; Varda M; Schiff R; Giuliano A; Cui X
    Clin Breast Cancer; 2015 Dec; 15(6):448-457.e2. PubMed ID: 26248960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early versus late distant metastasis and adjuvant chemotherapy alone versus both radiotherapy and chemotherapy in molecular apocrine breast cancer.
    Liu X; Yang Y; Feng X; Shen H; Liu J; Liu X; Niu Y
    Oncotarget; 2016 Aug; 7(31):48905-48917. PubMed ID: 27340922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.